孟鲁司特钠联合复方福尔可定口服液治疗喘息性支气管肺炎的疗效观察

Effect of montelukast sodium combined with compound pholcodine oral liquid on asthmatic bronchopneumonia

目的探讨孟鲁司特钠联合复方福尔可定口服液治疗喘息性支气管肺炎的疗效。方法选取100例于2021年5月-2022年8月期间就诊的喘息性支气管肺炎患者进行临床研究,经单双数法分为对照组、观察组,每组患者50例。两组患者均采用常规对症治疗,对照组联用复方福尔可定口服液治疗,观察组联用孟鲁司特钠、复方福尔可定口服液治疗。结果观察组治疗有效率大于对照组,有统计学意义(P<0.05)。观察组治疗时间短于对照组,有统计学意义(P<0.05)。用药7d后观察组的肺功能指标高于对照组,有统计学意义(P<0.05)。结论喘息性支气管肺炎联合应用孟鲁司特钠、复方福尔可定口服液治疗,临床治疗效果显著,治疗时间明显更短,肺功能指标改善显著,值得临床推广。

Objective To investigate the efficacy of montelukast sodium combined with compound pholcodine oral liquid in the treatment of asthmatic bronchopneumonia.Method From May 2021 to August 2022,100 patients with asthmatic bronchopneumonia were selected for clinical research.They were divided into control group and observation group by single and even number method,with 50 patients in each group.The patients in the two groups were treated with conventional symptomatic treatment.The control group was treated with compound pholcodine oral liquid,and the observation group was treated with montelukast sodium and compound pholcodine oral liquid.Result The effective rate of the observation group was higher than that of the control group,and the ratio was statistically significant(P<0.05).The treatment time in the observation group was shorter than that in the control group,with a statistically significant ratio(P<0.05).The pulmonary function indexes of the observation group were higher than those of the control group after 7 days of treatment,with a statistically significant ratio(P<0.05).Conclusion The combination of montelukast sodium and compound pholcodine oral liquid in the treatment of asthmatic bronchopneumonia has significant clinical effect,shorter treatment time and significant improvement of lung function indicators,which is worthy of clinical promotion.